CMOs to benefit from double digit approvals for ADCs in the next 3 years

9 Oct 2018

Therapeutic ADC market expected to reach $4 billion by 2023.

The global ADC therapeutics market is expected to grow to $4 billion by 2023, with double digit approvals within 3 years, according to a new analysis in the CPhI Annual Report.

CMOs to benefit from double digit approvals for ADCs in the next 3 years

CPhI Annual Report expert Vivek Sharma, CEO of Piramal Pharma Solutions, expects the global market for ADCs to grow at around 19% CAGR between 2017 and 2030 and reach an estimated value of $4 billion in the next 5 years, with 17 drugs that are either approved or in late stages of clinical development, catalysing such growth.

“The last few years have seen a progressive evolution of targets from first to second and third generation Antibody Drug Conjugates (ADCs), which is now accelerating growth as new compounds are more targeted, more druggable and potentially have a better chance for approval.” commented Vivek Sharma.

The understanding of site-specificity and homogenously conjugated ADCs has accelerated the FDA approval rate and has led to dramatic increase in the number of clinical trials, especially in solid tumours. In total there are now 600 clinical trials being conducted worldwide on ADCs, with 202 ADCs entering clinical trials – out of which 116 are actively progressing. Most encouragingly, there has been an increase of 30% in the last 12 months with 23 new ADCs entering clinical trials.

The report outlines that CMO’s and CDMO's are particularly well set to capitalise on this growing therapeutic product class, and may even lead to new business models, such as co-development partnerships, particularly amongst smaller and medium-sized biotechs.

“The global market for ADCs is expected to be driven by the advancement in medical technology, rising incidence of cancer, and an increasing demand for biologic therapies. In the quest for more targeted therapies and potentially more clinically efficacious drugs, bio/pharma companies are increasing their research and product development in biologics” added Sharma.

Due to technical challenges associated with ADC manufacturing and the substantial investment involved on safety and hazardous material equipment, Vivek estimates that around 70% of ADC manufacturing is outsourced to CMOs. This is expected to rise, particularly for horizontally integrated CDMOs, along with co-development business models, driven by biotechs and smaller companies that need specialist development expertise and facilities.

In the long term, the Annual Report also highlights that ADCs are now being utilized in other therapeutic products classes beyond oncology. Specifically, ADCs are projected to provide more targeted therapeutics in infectious diseases (against multidrug-resistant bacteria) and chronic conditions such as autoimmune and cardiovascular diseases.

CPhI Brand Director Europe, Orhan Caglayan added: “The findings in the full CPhI Annual Report further reinforces that there is a clear bridge now forming between small and large molecule industries, with the cross sharing of knowledge in the ADC market leading to less clinical attrition and greater approvals. So whilst it is clearly good news for CPhI and bioLIVE – as we combine small and large molecule exhibitions in 2018 – the market also looks extremely promising for CDMOs, and the wider outsourcing industry with over 70% of future manufacturing set to be contracted to specialist providers. So I encourage all of our attendees at CPhI Worldwide to engage both these findings and with the wider industry this week – by establishing new partnerships we will help accelerate development of the global market."

Read More

Related news

EU FMD - time is running out!

EU FMD - time is running out!

13 Nov 2018

Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.

Read more 
Proprietary nasal delivery formulation of diazepam reaches NDA

Proprietary nasal delivery formulation of diazepam reaches NDA

7 Nov 2018

The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.

Read more 
DSCSA one-month countdown!

DSCSA one-month countdown!

30 Oct 2018

With only a month to go, it really is too late to start trying to develop an in-house solution.

Read more 
Global pharma set for strong year

Global pharma set for strong year

23 Oct 2018

Eight of the top ten pharma nations reporting improving market conditions.

Read more 
Generics companies to move away from little white pills

Generics companies to move away from "little white pills"

14 Oct 2018

Accepting more complexity and risk is key for those generics companies seeking competitive differentiation by diversifying their product portfolios.

Read more 
Movement on the market reflected at CPhI Worldwide 2018

Movement on the market reflected at CPhI Worldwide 2018

3 Oct 2018

Companies new to CPhI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.

Read more 
Sanofi to refocus two global business units

Sanofi to refocus two global business units

19 Sep 2018

The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.

Read more 
Moulds & Tooling: A European success story

Moulds & Tooling: A European success story

19 Sep 2018

While not quite an endangered species, the past fifteen years have not been easy ones for many European mould makers. Many, but not all, and IGS GeboJagema is a case in point – a case that shows the difference automation and focus can make. By Karen La...

Read more 
Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

18 Sep 2018

China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.

Read more 
Exciting skincare to protect against blue light emitted by phones and devices

Exciting skincare to protect against blue light emitted by phones and devices

10 Sep 2018

Novel, dual-acting product revitalizes and protects skin against blue light and environmental aggressors around the clock.

Read more